Clinical Scorecard: Assessment of the Shufeng Huashi formula's effectiveness and safety in treating post-infectious cough: a protocol for a randomized controlled trial

At a Glance

Key Highlights

• Study evaluates the efficacy and safety of the Shufeng Huashi formula.
• Randomized, double-blind, placebo-controlled design.
• Primary outcome measure is cough relief rate on day 14.
• Secondary outcomes include cough symptom scores and cough cure rate.
• Adverse events will be monitored throughout the study.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of PIC based on persistent cough following respiratory infection.

Management

• Current treatments primarily involve symptomatic relief using antitussives and antihistamines.

Monitoring & Follow-up

• Adverse events will be recorded during the trial.

Risks

• Current pharmacological treatments may have side effects such as somnolence and decreased appetite.

Patient & Prescribing Data

Adults with post-infectious cough, particularly those experiencing symptoms for 3 to 8 weeks.

The Shufeng Huashi formula is designed to address symptoms associated with Wind invasion and Dampness obstruction.

Clinical Best Practices

• Consider TCM approaches for patients with PIC, especially when conventional treatments are ineffective.
• Monitor for adverse events when using TCM formulations.

Related Resources & Content

• Clinical trial registration